Kollmannsberger, C. K., Hurwitz, H., Cleary, J. M., Strickler, J. H., Drouin, M. A., Juretic, M., … Shapiro, G. (2012). MGCD265, a multitargeted oral tyrosine kinase receptor inhibitor of Met and VEGFR: Dose-escalation phase I study. In JOURNAL OF CLINICAL ONCOLOGY (Vol. 30). Chicago, IL: AMER SOC CLINICAL ONCOLOGY.

Kollmannsberger, Christian K., Herbert Hurwitz, James M. Cleary, John H. Strickler, Michel A. Drouin, Manuela Juretic, Wendy Hunt, et al. “MGCD265, a multitargeted oral tyrosine kinase receptor inhibitor of Met and VEGFR: Dose-escalation phase I study.” In JOURNAL OF CLINICAL ONCOLOGY, Vol. 30. AMER SOC CLINICAL ONCOLOGY, 2012.

Kollmannsberger CK, Hurwitz H, Cleary JM, Strickler JH, Drouin MA, Juretic M, et al. MGCD265, a multitargeted oral tyrosine kinase receptor inhibitor of Met and VEGFR: Dose-escalation phase I study. In: JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY; 2012.

Kollmannsberger, Christian K., et al. “MGCD265, a multitargeted oral tyrosine kinase receptor inhibitor of Met and VEGFR: Dose-escalation phase I study.” JOURNAL OF CLINICAL ONCOLOGY, vol. 30, no. 15, AMER SOC CLINICAL ONCOLOGY, 2012.

Kollmannsberger CK, Hurwitz H, Cleary JM, Strickler JH, Drouin MA, Juretic M, Hunt W, Reid GK, Maroun CR, Bonfils C, Wang J, Karam A, Besterman JM, Mehran M, Shapiro G. MGCD265, a multitargeted oral tyrosine kinase receptor inhibitor of Met and VEGFR: Dose-escalation phase I study. JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY; 2012.